Compare Li Auto Inc (LI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Moderna, Inc. — how do they compare? Li Auto Inc trades at $12.28 (market cap $12.43B), while Moderna, Inc. trades at $59.25 (market cap $23.60B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| LI | MRNA | |
|---|---|---|
Market Cap | $12.43B | $23.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $30.84 | $81.80 |
52-Week Low | $11.74 | $22.36 |
Enterprise Value | $1.34B | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LI Auto trades at $12.42, up 0.24% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31B from $144.5B in 2024. Recent news highlights the launch of new SUV models like the Li L6, aiming to boost deliveries amid competitive pressures.
Outlook remains cautious with analyst consensus at Buy (43.75%) but near-term risks from intense EV competition and profitability challenges. The stock trades below the consensus price target of $14.80, offering potential upside if execution improves, but investors face headwinds from margin pressure and volatile cash flows.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
